DE60117568T2 - Kondensierte pyrazol derivate als protein kinase inhibitoren - Google Patents

Kondensierte pyrazol derivate als protein kinase inhibitoren Download PDF

Info

Publication number
DE60117568T2
DE60117568T2 DE60117568T DE60117568T DE60117568T2 DE 60117568 T2 DE60117568 T2 DE 60117568T2 DE 60117568 T DE60117568 T DE 60117568T DE 60117568 T DE60117568 T DE 60117568T DE 60117568 T2 DE60117568 T2 DE 60117568T2
Authority
DE
Germany
Prior art keywords
alkyl
formula
fluorophenyl
pyrazolo
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60117568T
Other languages
German (de)
English (en)
Other versions
DE60117568D1 (de
Inventor
JohnGlaxoSmithKline Michael North Carolina ALBERTI
RobertGlaxoSmithKline Ian BALDWIN
MuiGlaxoSmithKline North Carolina CHEUNG
StuartGlaxoSmithKline COCKERILL
Stephen Flack
Anthony Philip HARRIS
KendallGlaxoSmithKline David North Carolina JUNG
GregoryGlaxoSmithKline North Carolina PECKHAM
RobertGlaxoSmithKline Michael North Carolina PEEL
BadiangGlaxoSmithKline Jennifer North Carolina STANFORD
KirkGlaxoSmithKline North Carolina STEVENS
MarvinGlaxoSmithKline James North Carolina VEAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0020576A external-priority patent/GB0020576D0/en
Priority claimed from GBGB0020556.7A external-priority patent/GB0020556D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE60117568D1 publication Critical patent/DE60117568D1/de
Application granted granted Critical
Publication of DE60117568T2 publication Critical patent/DE60117568T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
DE60117568T 2000-08-22 2001-08-22 Kondensierte pyrazol derivate als protein kinase inhibitoren Expired - Fee Related DE60117568T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0020576A GB0020576D0 (en) 2000-08-22 2000-08-22 Fused pyrazole derivatives
GB0020556 2000-08-22
GB0020576 2000-08-22
GBGB0020556.7A GB0020556D0 (en) 2000-08-22 2000-08-22 Fused pyrazole derivatives
PCT/GB2001/003783 WO2002016359A1 (en) 2000-08-22 2001-08-22 Fused pyrazole derivatives being protein kinase inhibitors

Publications (2)

Publication Number Publication Date
DE60117568D1 DE60117568D1 (de) 2006-04-27
DE60117568T2 true DE60117568T2 (de) 2006-08-24

Family

ID=26244869

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60117568T Expired - Fee Related DE60117568T2 (de) 2000-08-22 2001-08-22 Kondensierte pyrazol derivate als protein kinase inhibitoren

Country Status (19)

Country Link
US (1) US7166597B2 (enExample)
EP (1) EP1311507B1 (enExample)
JP (1) JP2004506736A (enExample)
KR (1) KR20030040419A (enExample)
AR (1) AR034261A1 (enExample)
AT (1) ATE318814T1 (enExample)
AU (1) AU2001282318A1 (enExample)
BR (1) BR0113448A (enExample)
CA (1) CA2420024A1 (enExample)
DE (1) DE60117568T2 (enExample)
ES (1) ES2259331T3 (enExample)
HU (1) HUP0400757A2 (enExample)
IL (1) IL154402A0 (enExample)
MX (1) MXPA03001593A (enExample)
NO (1) NO20030779L (enExample)
PE (1) PE20020506A1 (enExample)
PL (1) PL362130A1 (enExample)
UY (1) UY26899A1 (enExample)
WO (1) WO2002016359A1 (enExample)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
WO2002048147A2 (en) 2000-12-15 2002-06-20 Glaxo Group Limited Pyrazolopyridines
AU2002239348A1 (en) 2000-12-15 2002-06-24 Glaxo Group Limited Pyrazolopyridine derivatives
JP2004529119A (ja) * 2001-03-08 2004-09-24 スミスクライン ビーチャム コーポレーション ピラゾロピリジン誘導体
US7034030B2 (en) 2001-03-30 2006-04-25 Smithkline Beecham Corporation Pyralopyridines, process for their preparation and use as therapeutic compounds
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
EP1377575B1 (en) * 2001-04-10 2006-07-05 SmithKline Beecham Corporation Antiviral pyrazolopyridine compounds
WO2002088124A2 (en) 2001-04-27 2002-11-07 Smithkline Beecham Corporation Pyrazolo'1,5-a!pyridine derivatives
CN1951939A (zh) 2001-05-24 2007-04-25 伊莱利利公司 作为药物的新的吡唑衍生物
US7186714B2 (en) 2001-06-21 2007-03-06 Smithkline Beecham Corporation Imidazo[1,2-α]pyridine derivatives for the prophylaxis and treatment of herpes viral infections
US20040235794A1 (en) * 2001-09-04 2004-11-25 Shinji Nakade Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
DE60211539T2 (de) 2001-10-05 2006-09-21 Smithkline Beecham Corp. Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion
GB0124934D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124932D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
DE60222465T2 (de) 2001-12-11 2008-06-05 Smithkline Beecham Corp. Pyrazolopyridin-derivate als antiherpesmittel
DE60334651D1 (de) * 2002-02-12 2010-12-02 Glaxosmithkline Llc Nicotinamide und deren Verwendung als P38 Inhibitoren
DE60331219D1 (de) 2002-03-28 2010-03-25 Eisai R&D Man Co Ltd Azaindole als hemmstoffe von c-jun n-terminalen kinasen
KR20040111445A (ko) 2002-03-28 2004-12-31 에자이 가부시키가이샤 신경퇴행성 질환 치료용 ｃ─Ｊｕｎ Ｎ─말단 키나아제억제제로서의 ７─아자인돌
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
GB0209891D0 (en) * 2002-04-30 2002-06-05 Glaxo Group Ltd Novel compounds
WO2003095455A2 (en) 2002-05-10 2003-11-20 Smithkline Beecham Corporation Substituted pyrazolopyrimidines
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
GB0217783D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
GB0217757D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
AR040726A1 (es) * 2002-07-31 2005-04-20 Smithkline Beecham Corp Compuesto de 2- fenilpiridin-4-il-heterociclico, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
ATE450258T1 (de) 2002-09-18 2009-12-15 Pfizer Prod Inc Neue pyrazol-verbindungen als hemmer des transformierenden wachstumsfaktors (tgf)
CN1681810A (zh) 2002-09-18 2005-10-12 辉瑞产品公司 作为转化生长因子(tgf)抑制剂的新的噁唑和噻唑化合物
CN1681809A (zh) 2002-09-18 2005-10-12 辉瑞产品公司 作为转化生长因子(tgf)抑制剂的新的异噻唑和异噁唑化合物
HRP20050252A2 (en) 2002-09-18 2005-10-31 Pfizer Products Inc. Novel imidazole compounds as transforming growth factor (tfg) inhibitors
MXPA05002982A (es) 2002-09-18 2005-06-22 Pfizer Prod Inc Derivados de triazol como inhibidores del factor de crecimiento transformante (tgf).
US7153863B2 (en) 2002-10-03 2006-12-26 Smithkline Beecham Corporation Therapeutic compounds based on pyrazolopyridline derivatives
DE602004029145D1 (de) 2003-02-27 2010-10-28 Palau Pharma Sa Pyrazolopyridin-derivate
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
GB0305142D0 (en) 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
US7612086B2 (en) 2003-05-16 2009-11-03 Eisai R & D Management Co. Ltd. JNK inhibitors
SE0301906D0 (sv) * 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
GB0318814D0 (en) * 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
GB0402140D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402138D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
MY143245A (en) * 2004-04-28 2011-04-15 Mitsubishi Tanabe Pharma Corp 4- 2-(cycloalkylamino)pyrimidin-4-yl-(phenyl)-imidazolin-2-one derivatives as p38 map-kinase inhibitors for the treatment of inflammatory diseases
CA2569404A1 (en) * 2004-06-04 2005-12-22 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
US20080051416A1 (en) * 2004-10-05 2008-02-28 Smithkline Beecham Corporation Novel Compounds
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
US7485725B1 (en) * 2004-11-12 2009-02-03 Frontier Scientific, Inc. Substituted pyridines
US7812022B2 (en) 2004-12-21 2010-10-12 Glaxosmithkline Llc 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
JP5132319B2 (ja) * 2004-12-21 2013-01-30 スミスクライン ビーチャム コーポレーション ２−ピリミジニルピラゾロピリジンＥｒｂＢキナーゼ阻害剤
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
CN101326182B (zh) * 2005-12-05 2011-09-28 史密丝克莱恩比彻姆公司 2-嘧啶基吡唑并吡啶ErbB激酶抑制剂
WO2007079185A2 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
AU2007258567B2 (en) * 2006-06-06 2012-04-19 Medicinova, Inc. Substituted pyrazolo (1,5-alpha) pyridine compounds and their methods of use
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US8158656B2 (en) * 2008-05-16 2012-04-17 Shenzhen Chipscreen Biosciences Ltd. 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
EP2310012B1 (en) * 2008-06-30 2015-03-04 Janssen Pharmaceutica N.V. Process for the preparation of substituted pyrimidine derivatives
US8198449B2 (en) 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7994171B2 (en) 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8293909B2 (en) 2008-09-11 2012-10-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8048887B2 (en) 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
ES2417355T3 (es) * 2009-05-19 2013-08-07 Dow Agrosciences Llc Compuestos y métodos para el control de hongos
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
CN101906076B (zh) 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
TW201102387A (en) * 2009-06-08 2011-01-16 Medicinova Inc Substituted pyrazolo[1,5-a]pyridine compounds having multi-target activity
US8502789B2 (en) 2010-01-11 2013-08-06 Smart Technologies Ulc Method for handling user input in an interactive input system, and interactive input system executing the method
EP2360158A1 (en) * 2010-02-18 2011-08-24 Almirall, S.A. Pyrazole derivatives as jak inhibitors
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
US8324212B2 (en) 2010-02-25 2012-12-04 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8354410B2 (en) 2010-03-11 2013-01-15 Bristol-Meyers Squibb Company Compounds for the treatment of hepatitis C
EP2402335A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
EP2402336A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
US8445497B2 (en) 2010-06-30 2013-05-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
CN103958518B (zh) * 2011-10-06 2017-07-04 拜耳知识产权有限责任公司 杂环基吡啶基吡唑/杂环基嘧啶基吡唑
US9303020B2 (en) 2012-02-08 2016-04-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
PL2925757T3 (pl) * 2012-11-19 2018-06-29 Novartis Ag Związki i kompozycje do leczenia chorób pasożytniczych
GB201321733D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
JP2017500362A (ja) * 2013-12-26 2017-01-05 イグナイタ インコーポレイテッド ピラゾロ［１，５−ａ］ピリジン誘導体およびその使用方法
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
CN109563095B (zh) * 2016-06-02 2021-10-29 细胞基因公司 动物和人抗疟剂
JP6949057B2 (ja) * 2016-06-02 2021-10-13 セルジーン コーポレイション 動物及びヒトの抗トリパノソーマならびに抗リーシュマニア薬
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN110563626B (zh) * 2019-09-04 2023-03-10 天津中医药大学 一种1h-氮杂环丙烯类化合物及其合成方法
EP4660192A1 (en) * 2020-08-05 2025-12-10 The General Hospital Corporation Salt inducible kinase inhibitors
JP2025532184A (ja) * 2022-07-29 2025-09-29 ベイラー カレッジ オブ メディスン 神経栄養因子受容体チロシンキナーゼ（ｎｔｒｋ）阻害剤およびそれを使用する方法

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
EP0151962A3 (en) 1984-01-25 1985-10-02 Beecham Group Plc Pyrazolopyridine derivatives
GB8404584D0 (en) 1984-02-22 1984-03-28 Beecham Group Plc Compounds
GB8404586D0 (en) 1984-02-22 1984-03-28 Beecham Group Plc Compounds
US5002941A (en) 1985-12-12 1991-03-26 Smithkline Beecham Corporation Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
US4925849A (en) 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
US5155114A (en) 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
DE3919348A1 (de) 1988-06-16 1989-12-21 Ciba Geigy Ag Mikrobizide mittel
GB8901423D0 (en) * 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
WO1991000092A1 (en) 1989-06-13 1991-01-10 Smithkline Beecham Corporation Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
AU622330B2 (en) 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
EP0430033A3 (en) 1989-11-24 1991-09-11 Ciba-Geigy Ag Microbicidal agents
EP0533837A4 (en) 1990-06-12 1994-11-17 Smithkline Beecham Corp Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases
GB9015764D0 (en) 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
EP0497258B1 (en) 1991-01-29 2002-01-02 Fujisawa Pharmaceutical Co., Ltd. Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer
GB9107513D0 (en) 1991-04-10 1991-05-29 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
PT533268E (pt) 1991-09-18 2002-02-28 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d
US5246943A (en) 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
TW240217B (enExample) 1992-12-30 1995-02-11 Glaxo Group Ltd
GB2273930A (en) 1992-12-30 1994-07-06 Glaxo Group Ltd Benzanilide derivatives
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
IL108630A0 (en) 1993-02-18 1994-05-30 Fmc Corp Insecticidal substituted 2,4-diaminoquinazolines
GB2276161A (en) 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benzanilide derivatives
GB2276162A (en) 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benazilide derivatives
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
AU686654B2 (en) 1993-08-31 1998-02-12 Pfizer Inc. 5-arylindole derivatives
EP0716656A1 (en) 1993-09-03 1996-06-19 Smithkline Beecham Plc Amide derivatives as 5ht1d receptor antagonists
EP0724580A1 (en) 1993-10-19 1996-08-07 Smithkline Beecham Plc Benzanilide derivatives as 5ht-1d receptor antagonists
JPH09506101A (ja) 1993-12-07 1997-06-17 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ１ｄ拮抗薬として有用な複素環式ビフェニリルアミド類
GB9326008D0 (en) 1993-12-21 1994-02-23 Smithkline Beecham Plc Novel compounds
GB9408577D0 (en) 1994-04-29 1994-06-22 Fujisawa Pharmaceutical Co New compound
JPH09512804A (ja) 1994-05-06 1997-12-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５−ｈｔ１ｄアンタゴニストとして有用なビフェニルカルボキシアミド類
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
PL322623A1 (en) * 1995-04-04 1998-02-02 Glaxo Group Ltd Derivatives of imidazo [1,2-a] pyridine
GB9507203D0 (en) 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
JPH11507669A (ja) 1995-06-12 1999-07-06 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ−２インヒビターとロイコトリエンｂ▲下４▼受容体アンタゴニストの組合せによる炎症と炎症関連疾患の治療
US5700816A (en) 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
ATE301457T1 (de) 1995-06-12 2005-08-15 Searle & Co Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
BR9609523A (pt) 1995-07-10 2001-11-13 Dow Chemical Co Composição, método de cura de látex e composto
US6174887B1 (en) 1995-08-22 2001-01-16 Japan Tobacco Inc. Amide compounds and use of the same
IL125223A0 (en) 1996-01-11 1999-03-12 Smithkline Beecham Corp Novel substituted imidazole compounds
FR2757059B1 (fr) 1996-12-12 1999-01-29 Rhone Poulenc Rorer Sa Nouvelle application therapeutique des derives du pyrrole
FR2757166B1 (fr) 1996-12-12 1999-01-29 Rhone Poulenc Rorer Sa Derives du pyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent
US6147080A (en) 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5945418A (en) 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
WO1998047899A1 (en) * 1997-04-24 1998-10-29 Ortho-Mcneil Corporation, Inc. Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
US6087496A (en) 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
RU2249591C2 (ru) 1997-05-22 2005-04-10 Дж.Д. Серл Энд Ко. 3(5)-гетероарилзамещенные пиразолы в качестве ингибиторов киназы p38
JP2002504909A (ja) 1997-06-13 2002-02-12 スミスクライン・ビーチャム・コーポレイション 新規な置換ピラゾールおよびピラゾリン化合物
CA2295762A1 (en) 1997-07-02 1999-01-14 Ravi Shanker Garigipati Novel cycloalkyl substituted imidazoles
DK1032575T3 (da) 1997-09-05 2003-10-20 Glaxo Group Ltd 2,3-diaryl-pyrazol(1,5-b)pyridazinderivater, deres fremstilling og anvendelse som cyclooxygenase 2 (COX-2) inhibitor
DE69830513T2 (de) 1997-12-22 2006-03-16 Bayer Pharmaceuticals Corp., West Haven HEMMUNG DER p38 KINASE UNTER VERWENDUNG VON SYMMETRISCHEN UND ASYMMETRISCHEN DIPHENYLHARNSTOFFEN
DE19817461A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue substituierte Benzamide, deren Herstellung und Anwendung
EP1077971A1 (en) * 1998-05-14 2001-02-28 G.D. SEARLE & CO. 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
PT1077931E (pt) 1998-05-15 2005-03-31 Astrazeneca Ab Derivados de bezamida para o tratamento de doencas mediadas por citocinas
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
US6130235A (en) 1998-05-22 2000-10-10 Scios Inc. Compounds and methods to treat cardiac failure and other disorders
FR2779724B1 (fr) 1998-06-10 2001-04-20 Rhone Poulenc Rorer Sa Derives du pyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent
KR20010082184A (ko) 1998-08-28 2001-08-29 추후제출 p38-α 키나제의 저해체
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
CA2337755C (en) 1998-09-18 2008-07-29 Vertex Pharmaceuticals Incorporated Inhibitors of p38
AR021055A1 (es) * 1998-11-03 2002-06-12 Glaxo Group Ltd Derivados de pirazolopiridina
WO2000039116A1 (en) * 1998-12-25 2000-07-06 Teikoku Hormone Mfg. Co., Ltd. Aminopyrazole derivatives
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
EP1157025B1 (en) 1999-02-27 2004-03-10 Glaxo Group Limited Pyrazolopyridines
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
US6509361B1 (en) 1999-05-12 2003-01-21 Pharmacia Corporation 1,5-Diaryl substituted pyrazoles as p38 kinase inhibitors
JP2003500382A (ja) 1999-05-24 2003-01-07 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子の阻害剤
JP2003500387A (ja) 1999-05-24 2003-01-07 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子の阻害剤
CA2374793A1 (en) 1999-05-24 2000-11-30 Penglie Zhang Inhibitors of factor xa
CA2376785A1 (en) 1999-06-28 2001-01-04 Janssen Pharmaceutica N.V. Benzimidazoles and imidazopyridines as respiratory syncytial virus replication inhibitors
GB9919778D0 (en) * 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
PT1140939E (pt) 1999-11-10 2005-05-31 Ortho Mcneil Pharm Inc 2-aril-3-(heteroaril)- imidazo [1,2-alfa] pirimidinas substituidas, e formulacoes farmaceuticas e metodos relacionados
WO2001070695A1 (en) 2000-03-22 2001-09-27 Vertex Pharmaceuticals Incorporated Pyridine derivatives as inhibitors of p38
DE60103752T2 (de) 2000-04-28 2005-07-14 Glaxo Group Ltd., Greenford Verfahren zur herstellung von pyrazolopyridinderivaten
CN1429223A (zh) 2000-05-18 2003-07-09 第一制药株式会社 新颖苯并呋喃衍生物
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AUPQ969800A0 (en) 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
PL366376A1 (en) 2000-11-17 2005-01-24 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
WO2002048147A2 (en) 2000-12-15 2002-06-20 Glaxo Group Limited Pyrazolopyridines
AU2002239348A1 (en) 2000-12-15 2002-06-24 Glaxo Group Limited Pyrazolopyridine derivatives
DE10063008A1 (de) 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
WO2002088124A2 (en) * 2001-04-27 2002-11-07 Smithkline Beecham Corporation Pyrazolo'1,5-a!pyridine derivatives
US6756498B2 (en) 2001-04-27 2004-06-29 Smithkline Beecham Corporation Process for the preparation of chemical compounds
WO2003000682A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
GB0124933D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124928D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124932D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
DE60334651D1 (de) 2002-02-12 2010-12-02 Glaxosmithkline Llc Nicotinamide und deren Verwendung als P38 Inhibitoren
GB0209891D0 (en) 2002-04-30 2002-06-05 Glaxo Group Ltd Novel compounds
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
US20040038014A1 (en) * 2002-08-20 2004-02-26 Donaldson Company, Inc. Fiber containing filter media
GB0308201D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
CA2534990A1 (en) 2003-07-25 2005-02-10 Novartis Ag P-38 kinase inhibitors
GB0318814D0 (en) 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
GB0329572D0 (en) 2003-12-20 2004-01-28 Astrazeneca Ab Amide derivatives

Also Published As

Publication number Publication date
EP1311507A1 (en) 2003-05-21
HUP0400757A2 (hu) 2004-07-28
AU2001282318A1 (en) 2002-03-04
WO2002016359A1 (en) 2002-02-28
US7166597B2 (en) 2007-01-23
CA2420024A1 (en) 2002-02-28
DE60117568D1 (de) 2006-04-27
JP2004506736A (ja) 2004-03-04
IL154402A0 (en) 2003-09-17
EP1311507B1 (en) 2006-03-01
US20040053942A1 (en) 2004-03-18
NO20030779D0 (no) 2003-02-19
ES2259331T3 (es) 2006-10-01
ATE318814T1 (de) 2006-03-15
UY26899A1 (es) 2002-03-22
PL362130A1 (en) 2004-10-18
AR034261A1 (es) 2004-02-18
NO20030779L (no) 2003-04-07
BR0113448A (pt) 2003-06-17
PE20020506A1 (es) 2002-07-09
MXPA03001593A (es) 2003-06-04
KR20030040419A (ko) 2003-05-22

Similar Documents

Publication Publication Date Title
DE60117568T2 (de) Kondensierte pyrazol derivate als protein kinase inhibitoren
US11780823B2 (en) Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors
AU2009281822B2 (en) cMET inhibitors
US10105370B2 (en) 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
US8846673B2 (en) Azaindazoles as kinase inhibitors and use thereof
NL1029016C2 (nl) Tetrahydronafthyridinederivaten.
JP4782117B2 (ja) ピロロトリアジンキナーゼ阻害剤
US20240270759A1 (en) Preparation of SHP2 phosphatase inhibitors and its applications
US20070135466A1 (en) Pyrrolopyridines useful as inhibitors of protein kinase
US9956220B2 (en) Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors
SK3542002A3 (en) Pteridinones as kinase inhibitors
JP2009528989A (ja) Ｔｌｒ７変調剤としての３−デアザプリン誘導体
EP2454257A1 (en) Pyrrolopyridine inhibitors of kinases
JP2007507546A (ja) キナーゼ阻害剤としての１，６−二置換アザベンゾイミダゾールの調製
JP2009506004A (ja) ｐ３８ＭＡＰキナーゼ阻害剤としての縮合ピラゾール
US9475817B2 (en) Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
KR102404650B1 (ko) 포스포디에스테라아제 10a 억제제로서 융합된 트리아졸 유도체
US10647727B2 (en) Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee